2nd Quarter - Amendment

NATIONAL VENTURE CAPITAL ASSOCIATION for NATIONAL VENTURE CAPITAL ASSOCIATION

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$720,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Amendment (this page) Jul 21, 2014 $720,000 Replaced
2nd Quarter - Amendment Jan 14, 2016 $720,000 Yes

What was lobbied

8 issue areas, each in the filer's own words, with who lobbied on it and where.

Banking BAN

Implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (PL 111-203) Implementation of the JOBS Act Review of decimalization study by the SEC, required under the JOBS Act.

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN —
KELLY SLONE —

Contacted: Federal Communications Commission (FCC); SENATE; Securities & Exchange Commission (SEC); Treasury, Dept of; White House Office; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Telecommunications TEC

HR 1468 Secure IT Act: Bills to protect critical infrastructure against cyber based espionage, IP theft and terror attacks; Privacy and Information Sharing issues; S.21 Cybersecurity and American Cyber Competitiveness Act of 2013; HR 624 Cyber Intelligence Sharing and Protection Act (CISPA); Net Neutrality: Keep the internet free and open -- no "fast lanes".

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN —
KELLY SLONE —

Contacted: Securities & Exchange Commission (SEC); Treasury, Dept of; Federal Communications Commission (FCC); White House Office; SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: H.R. 624 (113th), S. 21 (113th), H.R. 1468 (113th)

Energy/Nuclear ENG

Cleantech and Energy Policy Issues. New Energy Innovation Tax issues; ARPA-E Funding; HR 2609 FY 2015 Energy ad Water Appropriations. Senate Finance Energy Tax Paper.

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN —
KELLY SLONE —

Contacted: HOUSE OF REPRESENTATIVES; White House Office; Federal Communications Commission (FCC); SENATE; Food & Drug Administration (FDA); Securities & Exchange Commission (SEC); Treasury, Dept of

Bills named: H.R. 2609 (113th)

Science/Technology SCI

Basic science research funding HR 2981 Technology and Research National Security and Future Economic Resiliency Act (TRANSFER Act).

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN —
KELLY SLONE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Securities & Exchange Commission (SEC); White House Office; Federal Communications Commission (FCC); Treasury, Dept of

Bills named: H.R. 2981 (113th)

Taxation/Internal Revenue Code TAX

S.232/HR 1295 Medical Device Access and Innovation Protection Act: would repeal the medical device tax as part of the ACA; S. Con Resolution 8: an original resolution setting forth the Congressional Budget for FY2014 which would repeal the medical device tax but not identify a pay for: HR 523 Protect the Medical Innovation Act of 2013: Taxation of carried interest; capital gains tax policy; energy tax extenders; Energy Innovation Tax; Ways and Means tax reform discussion draft; Senate Finance tax discussion drafts; Chairman Dave Camp draft.

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN —
KELLY SLONE —

Contacted: White House Office; Food & Drug Administration (FDA); Securities & Exchange Commission (SEC); Federal Communications Commission (FCC); Treasury, Dept of; SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 232 (113th), H.R. 523 (113th), H.R. 1295 (113th)

Copyright/Patent/Trademark CPT

HR 3309, the Innovation Act of 2013; S. 866, Patent Quality Improvement Act; S. 1013, Patent Abuse Reduction Act; S. 1612, Patent Litigation Integrity Act; S. 1720, Patent Transparency & Improvement Act; Lobbied Congress on various patent litigation reforms that impact investment in the start-up ecosystem. Support the TROL Act, aimed at protecting businesses while preserving the ability of patent holders to legitimately protect their IP by increasing transparency with accountability in demand letters.

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN —
KELLY SLONE —

Contacted: White House Office; Treasury, Dept of; Federal Communications Commission (FCC); Securities & Exchange Commission (SEC); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Bills named: S. 866 (113th), S. 1013 (113th), S. 1720 (113th), H.R. 3309 (113th), S. 1612 (113th)

Health Issues HCR

No bill #: Lobbied Congress to work the FDA to create a new approval pathway that could help expedite the development of certain drugs that address unmet medical needs, referred to as a special medical use pathway which can be used for a broad set of discussions; HR 4302, the Protecting Access to Medicare Act of 2014, Section 216, Improving Medicare Policies and Clinical Diagnostic Laboratory Tests. No bill #: Lobbied Congress on the integrity of FDA's Special Protocol Assessment (SPA) process. Support language included in HR 4800, Agriculture, Rural Development, Food & Drug Admin., and Related Agencies Appropriations Act of 2015 and in S. 2389, the FY2015 Senate Agriculture, Rural Development, Food & Drug Admin., and Related Agencies Appropriations highlighting the importance of the FDA SPA process. Lobbied Congress on the need for a transparent regulatory pathway for market-based reimbursement for advanced diagnostics; No bill #: Lobbied Congress in support of the House E&C 21st Century Cures Initiative.

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN —
KELLY SLONE —

Contacted: Securities & Exchange Commission (SEC); White House Office; Food & Drug Administration (FDA); Federal Communications Commission (FCC); HOUSE OF REPRESENTATIVES; Treasury, Dept of; SENATE

Bills named: H.R. 4302 (113th), H.R. 4800 (113th), S. 2389 (113th)

Immigration IMM

HR 4178 American Entrepreneurship & Investment Act; S.189 Startup VISA Act of 2013; Gang of 8 Bipartisan Framework for Comprehensive Immigration Reform; Invest VISA, Entrepreneurial VISA, HR 2131 S744 Border Security, Economic Opportunity and Immigration Modernization Act.

LobbyistCovered position, as disclosed
EMILY BAKER —
JENNIFER DOWLING —
BOBBY FRANKLIN —
KELLY SLONE —

Contacted: White House Office; SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Securities & Exchange Commission (SEC); Treasury, Dept of; Federal Communications Commission (FCC)

Bills named: H.R. 4178 (113th), H.R. 2131 (113th), S. 189 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.